Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort DOI Creative Commons

Gerald Kevin Oluka,

Jackson Sembera,

Joseph Ssebwana Katende

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 143 - 143

Published: Jan. 29, 2025

Background: This study assessed the long-term dynamics of neutralizing antibodies in a Ugandan cohort primarily exposed to A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection prototype-based vaccination. Methods: We conducted 427-day retrospective analysis 41 participants across multiple waves, assessing binding antibody responses using in-house ELISA pseudotyped virus neutralization assays. quantified key variants, A.23.1, D614G, Delta, BA.4, capturing evolving immunity pandemic. Results: Neutralizing titers remained significantly higher than those highlighting solid memory infection. Consistently lower were observed for BA.4 all time points, aligning with its strong immune-evasion capability. Correlations between spike-directed IgG (S-IgG) concentrations stronger no correlation BA.4. ChAdOx1-S vaccination substantially elevated most notably essential role boosting immunity, even individuals initially low titers. Conclusions: Initial exposure variant triggered potent responses, shaping during subsequent exposures. These findings highlight importance accounting early viral exposures vaccine development public health planning. The distinctly response highlights need continuous antigenic monitoring timely updates protection emerging variants. Vaccination remains reinforcing sustaining

Language: Английский

Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort DOI Creative Commons

Gerald Kevin Oluka,

Jackson Sembera,

Joseph Ssebwana Katende

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 143 - 143

Published: Jan. 29, 2025

Background: This study assessed the long-term dynamics of neutralizing antibodies in a Ugandan cohort primarily exposed to A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection prototype-based vaccination. Methods: We conducted 427-day retrospective analysis 41 participants across multiple waves, assessing binding antibody responses using in-house ELISA pseudotyped virus neutralization assays. quantified key variants, A.23.1, D614G, Delta, BA.4, capturing evolving immunity pandemic. Results: Neutralizing titers remained significantly higher than those highlighting solid memory infection. Consistently lower were observed for BA.4 all time points, aligning with its strong immune-evasion capability. Correlations between spike-directed IgG (S-IgG) concentrations stronger no correlation BA.4. ChAdOx1-S vaccination substantially elevated most notably essential role boosting immunity, even individuals initially low titers. Conclusions: Initial exposure variant triggered potent responses, shaping during subsequent exposures. These findings highlight importance accounting early viral exposures vaccine development public health planning. The distinctly response highlights need continuous antigenic monitoring timely updates protection emerging variants. Vaccination remains reinforcing sustaining

Language: Английский

Citations

1